[Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].

Abstract

Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. Authors report a 12-year-old boy with infliximab refractory luminal Crohn's disease including 3 active perianal fistulas. The patient was treated successfully with adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody. After 10 weeks of therapy, the previously high activity index returned to normal and the fistulas were closed. Quality of life using validated questionnaire improved significantly also. Adalimumab might be a suitable therapy even in pediatric Crohn's disease patients with infliximab resistance.

• Authors: Gábor Veres, Réka Putz, Dolóresz Szabó, Kriszta Molnár, Hedvig Bodánszky, Antal Dezsofi, András Arató
• Journal: Orvosi hetilap (Orv Hetil) Vol. 150 Issue 40 Pg. 1858-60 (Oct 04 2009) ISSN: 0030-6002 [Print] Hungary
• Vernacular Title: Infliximab-rezisztens Crohn-beteg gyermek adalimumab-kezelése.
• PMID: 19789146 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Infliximab
• Adalimumab

Topics

• Adalimumab
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Child
• Crohn Disease (drug therapy)
• Drug Administration Schedule
• Drug Resistance
• Gastrointestinal Agents (therapeutic use)
• Humans
• Infliximab
• Male
• Quality of Life
• Treatment Outcome